Apotex wins first generic semaglutide approval, retatrutide aces Phase III, and the Foundayo vs oral Wegovy rivalry intensifies.
10 stories · Covering regulatory, clinical-trials, research, industry
The oral GLP-1 war is officially on: with both Foundayo (orforglipron) and oral Wegovy now on pharmacy shelves, the battle for the $100B+ obesity pill market is the dominant story. Apotex won the first-ever tentative FDA approval for generic semaglutide injection, signaling the eventual end of Novo Nordisk's monopoly. Novo fired back with Wegovy HD (higher-dose injectable) and new ORION data showing oral semaglutide outperforms Foundayo on weight loss. Meanwhile, retatrutide delivered impressive Phase III results for obesity + osteoarthritis, Stanford found ~10% of patients may be resistant to GLP-1 drugs, and GQ and The Atlantic brought peptides firmly into mainstream cultural conversation.
The FDA granted Apotex Corp. the first-ever tentative approval for a generic semaglutide injection equivalent to Ozempic/Wegovy. Actual market entry is blocked by Novo Nordisk patents until ~2032, but the milestone proves a complex peptide injectable can meet FDA generic equivalence standards.
Eli Lilly's triple-agonist retatrutide met all primary and key secondary endpoints in Phase III TRIUMPH-4. The 9mg and 12mg doses achieved significant weight loss and knee pain reduction at 68 weeks in patients with obesity and osteoarthritis. Seven more Phase III readouts expected in 2026.
Stanford researchers found approximately 10% of people may have resistance to GLP-1 drugs, limiting effectiveness for glucose regulation and weight loss. The study examined individual variation in how GLP-1 drugs slow gastric emptying.
Phase 3 SURMOUNT-4 data show patients who continued tirzepatide achieved further weight loss, while those switched to placebo regained ~14% body weight over 52 weeks. Findings underscore the need for long-term GLP-1/GIP therapy continuation.
Novo Nordisk received accelerated FDA approval for Wegovy HD, a higher-dose injectable semaglutide offering ~21% weight loss, with aggressive discount pricing to fight Lilly's market share gains.
Detailed comparison of Lilly's Foundayo (orforglipron) and Novo's oral Wegovy. Foundayo offers no food/water restrictions; oral Wegovy has brand familiarity and head start. Wall Street predicts slower initial Foundayo uptake.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
New ORION study results show oral semaglutide produced greater weight loss and better tolerability than rival orforglipron (Foundayo). Novo also introduced higher-dose Wegovy with aggressive discounts.
The Atlantic examines how GLP-1 pills are reshaping obesity treatment. The shift from weekly injections to daily pills addresses a major compliance barrier, though patients must continue therapy indefinitely.
Novo Nordisk entered a $2.1 billion partnership with Vivtex to develop oral delivery of biologic drugs, combining Novo's peptide expertise with Vivtex's GI formulation platform.